-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Acute graft anti-host disease (GVHD) is a common complication after hematopoietic stem cell transplantation (HSCT), resulting in an increased risk of adverse prognosis in patients.
standard prevention programs for GVHD, including calcium-adjusted neurophosphatase inhibitors with methotrexate or siromos.
found that the incidence of ACUTE GVHD at level II-IV was 34-51% within 100 days of HLA-matched allogeneic transplantation.
DPP-4, also known as CD26, is a T-cell trans-membrane subject with a wide range of activities, including insulin release, substring cell derivative factor 1 induced stem cell nesting, hematopoietic cytokine activity and T-cell immunity.
model study confirmed that CD26 is effective in preventing GVHD, and researchers recently examined the prevention effect of Sigredine on acute graft anti-host disease in patients with heterogeneic stem cell transplantation.
this study, a Phase II clinical study, examined the preventive effects of a combined treatment of siglitin, tekmos and siromos on acute GVHD level II-IV.
patients who started the standard isogenetic hematopoietic stem cell transplant program 1 day to the 14th day after the transplant, every 12 hours oral 600 mg of siglitin.
of the study was a 30% reduction in the incidence of acute GVHD level II-IV within 100 days, i.e. no more than 15%.
36 patients, with an average age of 46.
100 days after transplantation, 2 patients developed acute GVHD, while the occurrence rate of II-IV acute GVHD was 5%, the occurrence rate of III or IV acute GVHD was 3%, and the non-recurrence mortality rate of 1 year was 0.
recurrence or chronic GVHD occurred in 26% and 37%, respectively, within 1 year.
1 year, the no GVHD recurrence rate was 46%.
adverse events in patients who received Sigretin as a precaution were similar to between patients with other hematopoietic stem cell transplants.
study confirmed that addition of sigletin on the basis of his treatment of kemos and siromos significantly reduced the risk of level II-IV acute graft anti-host disease within 100 days of hematopoietic stem cell transplantation.
